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Abstract We studied the association between alanine amino-
transferase (ALT) and features of the metabolic syndrome in a
cohort of overweight and obese children aged 3–18 years. An
oral glucose tolerance test was performed in 443 consecutive
children from an obesity out-patient clinic (median age 11.2,
range 3.1–18.0 years; n=240 boys) of multi-ethnic origin.
The prevalence of the metabolic syndrome, insulin resistance,
elevated ALT (>30 IU/L), and the association of ALT with
(components of) the metabolic syndrome was assessed. The
metabolic syndrome was present in 26.9%. Elevated ALT
levels were found in 20.3%, with a higher prevalence in boys
than in girls (25.8% versus 13.8%, P<0.001). ALT was
associated with the prevalence of the metabolic syndrome,
insulin resistance, high triglycerides, and low HDL-
cholesterol after adjustment for gender, age, and BMI. In
conclusion, elevated ALT levels were highly prevalent and
associated with the metabolic syndrome, insulin resistance,
high triglycerides, and low HDL-cholesterol in an obese
multiethnic pediatric population.
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NAFLD Non-alcoholic fatty liver disease
ALT Alanine aminotransferase
SDS Standard deviation score
IDF International Diabetes Federation
Z-BMI Standard deviation score of BMI
Z-WC Standard deviation score of waist
circumference
Introduction
As in adults, the prevalence of obesity in children worldwide
as well as its cardiometabolic sequelae are rapidly increasing
[27]. Although criteria for the metabolic syndrome in
children and adolescents have only started to become
formally defined, components of the adult metabolic
syndrome, including central obesity, insulin resistance,
glucose intolerance, hypertriglyceridemia, low HDL-choles-
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terol and hypertension have been reported in pediatric
populations [16].
In adults, non-alcoholic fatty liver disease (NAFLD) and
the more advanced stage, i.e. non-alcoholic steatohepatitis,
are considered the hepatic manifestation of the metabolic
syndrome and are associated with type 2 diabetes and a
high risk of atherothrombotic cardiovascular disease [17].
Currently, NAFLD as a clinicopathologic condition is
associated with childhood obesity and considered a major
cause of abnormal liver function tests of unknown origin in
pediatric populations [25]. Insulin resistance and hyper-
insulinemia are regarded as critical factors in the pathogen-
esis of fatty liver disease. Conversely, fatty liver contributes
to hepatic insulin resistance leading to increased glucose
and triglyceride output by the liver and to lowered HDL-
cholesterol levels [17].
In adults, the estimated prevalence of NAFLD ranges
from 3% to 24% [8]. According to recently reported
autopsy findings, fatty liver was present in 13% of 742
deceased children and adolescents aged 2–19 years [24].
After adjustment for age, gender, and ethnicity, the
prevalence was 9.6%, increasing with age. Since obesity-
related NAFLD may be associated with cardiometabolic
risk factors in children, early identification of children at
risk for developing type 2 diabetes and cardiovascular
disease later in life is fundamental.
Alanine aminotransferase (ALT) is the liver enzyme with
the closest association with liver fat accumulation [23], and
consequently has been used as a circulating marker of
NAFLD.
In this study, we established the prevalence of (compo-
nents of) the metabolic syndrome, insulin resistance, and
additional cardiometabolic risk factors in an obese popula-
tion, and subsequently assessed the association of ALT with
the presence of these cardiometabolic risk factors.
Methods
Data on a cohort of children aged 3–18 years who attended
the pediatric obesity out-patient clinic at a general hospital
in the Netherlands (Slotervaart Hospital, Amsterdam) in the
period 2004–2007 were collected according to a prevailing
treatment protocol. Severity of obesity was classified
according to Dutch age- and gender-adjusted criteria from
the ‘Fourth National Growth Study’ [11]. Children who
used glucose- or lipid-lowering drugs, corticosteroids
(chronically), drugs acting on the central nervous system,
or children with (suspected) syndromes, type 1 diabetes, or
secondary causes of obesity such as hypothyroidism,
hypogonadism, and pituitary disorders were excluded from
the study. In total, 443 children of multiethnic origin were
included. None of the recruited subjects had a history of
alcohol abuse, and serologic tests for hepatitis B or C virus
were negative in all. Each child underwent an oral glucose
tolerance test (OGTT; 1.75 g glucose per kg of body
weight, with a maximum of 75 g), with concomitant
collection of blood samples for determination of fasting
lipids, insulin, and ALT. At the same time, BMI, waist
circumference, blood pressure, and Tanner’s pubertal stages
were assessed. BMI values were standardized according to
Dutch reference values using Z-scores (Z-BMI), which are
standard deviation score (SDS) [11]. Children with a SDS
from 1.1 to 2.3 were classified as overweight and children
with ≥2.3 SDS were classified as obese. Waist circumfer-
ence values were also standardized using Z-scores (Z-WC),
applying Dutch reference values (cut-off values were 1.3
SDS for overweight and 2.3 SDS for obesity) [10].
Table 1 shows the definitions of the cardiometabolic risk
factors and the metabolic syndrome. Glucometabolic disorders
were defined by the presence of either impaired fasting glucose
(IFG) or impaired glucose tolerance (IGT) or both, or type 2
diabetes, according to the IDF-criteria, with a cut-off point of
5.6 mmol/l for fasting glucose [2]. Hypertension was
established according to previously reported European
height- and gender-adjusted cut-off points [9], and lipid
levels were assessed according to international criteria
adjusted for age and gender [3]. The metabolic syndrome
was defined according to the presence of overweight or
obesity in addition to two of the components shown in Table
1 [28, 29]. Insulin resistance was assessed according to the
homeostasis model assessment for insulin resistance
(HOMA-IR): fasting plasma insulin (μU/l) × fasting glucose
(mmol/l) / 22.5 [18], with insulin resistance defined as
HOMA-IR ≥3.5 [15].
Table 1 Definition of (components of) the metabolic syndrome
Component Definition
1) Glucometabolic disorders Impaired fasting glucose (IFG):
fasting glucose ≥5.6 mmol/l
Impaired glucose intolerance (IGT):
2 h-glucose ≥7.8 and <11.0 mmol/l
Diabetes: fasting glucose ≥7.0 or 2 h-
glucose ≥11.0 mmol/l
2) Low HDL-cholesterol <p5 for age and gender
3) High Triglycerides >p95 for age and gender
4) High systolic or diastolic
blood pressure
>p95 for height and gender
The metabolic syndrome includes overweight or obesity and two or
more of the mentioned components
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We chose a cut-off value of ALT >30 IU/l, which was
shown to have the optimal sensitivity and specificity to
predict NAFLD in a comparable population [21] and was
further validated in the NHANES III study [26].
Laboratory analysis
Plasma glucose, ALT, and lipids were determined with
SYNCHRON LX 20 (Beckman Coulter, Galway, Ireland),
with intra-assay coefficients of variation (CV) of ≤3.5% for
ALT and ≤3% for plasma glucose and fasting lipids. LDL-
cholesterol was calculated with the Friedewald-formula
[12]. Plasma insulin was determined with a chemiluminis-
cent immunometric assay (Immulite 200 system, Siemens
Medical Diagnostics, Los Angeles, USA), intra-assay CV
3–6%, inter-assay CV 3–5%, detection-value 15 pmol/l.
Statistical analysis
Categorical data are presented as percentages, and continuous
data are presented as means ± standard deviation (SD), or
median (interquartile range [IQR]) for variables with a skewed
distribution. Differences in clinical and biochemical character-
istics were tested by Student’s t tests for continuous variables
and with χ2 tests for categorical data.
The presence of cardiometabolic risk factors and the
metabolic syndrome were determined according to gen-
der, ethnicity, and ALT values (normal ALT group:
ALT ≤30 IU/l and high ALT group: ALT >30 IU/l). To
assess the association between ALT (as continuous
variable) with (components of) the metabolic syndrome,
logistic regression analyses were applied. To investigate
the association between ALT and continuous metabolic
variables, multivariate linear regression analyses were
performed. In these models the individual metabolic
parameter was entered as independent variable and ALT
was entered as outcome variable, with additional adjust-
ment for age, gender, and Z-BMI. Effect modification by
pubertal stage, gender, and degree of obesity (overweight
vs. obese) was tested by entering interaction terms
(pubertal stage × ALT, gender × ALT, and degree of
obesity × ALT) into the models. Analyses were performed
with SPSS software (version 15.0 for Windows, SPSS
Inc., Chicago, IL). A two-sided P value <0.05 was
considered statistically significant and a two-sided P value
<0.1 was used to indicate effect modification.
Table 2 Baseline characteristics and prevalence of cariometabolic risk factors, stratified according to normal and high ALT
Total ALT ≤30 IU/l ALT >30 IU/l
N 443 353 90
Male/female 264 (54.2%) / 203 (45.8%) 178 (50.4%) / 175 (49.6%) 62 (68.9%) / 28 (31.1%)**
Pubertal 280 (63.2%) 217 (61.5%) 63 (70.0%)
Age (y) 11.2 (10.0–14.5) 11.2 (8.8–13.6) 11.5 (10.0–14.5)***
Z-BMI 2.8±0.5 2.8±0.5 2.9±0.5
Z-WC 3.9±1.2 3.8±1.2 4.3±1.1**
Systolic blood pressure (mmHg) 115 (108–122) 113 (108–121) 118 (110–127)
Diastolic blood pressure (mmHg) 70 (65–76) 70 (65–75) 73 (68–79)***
Fasting plasma glucose (mmol/l) 5.3±0.4 5.2±0.4 5.3±0.4
2-h plasma glucose (mmol/l) 5.8±1.0 5.8±0.9 6.0±1.2
Fasting plasma insulin (pmol/l) 102 (64–162) 96 (62–145) 131 (84–198)**
HOMA-IR 3.3 (2.0–5.4) 3.2 (2.0–5.0) 4.5 (2.5–6.7)**
Total cholesterol (mmol/l) 4.3±0.8 4.3±0.8 4.4±0.8
HDL-cholesterol (mmol/l) 1.1 (0.9–1.2) 1.1 (0.9–1.3) 1.0 (0.8–1.2)**
LDL-cholesterol (mmol/l) 2.8±0.7 2.8±0.7 2.9±0.6
Triglycerides (mmol/l) 0.8 (0.6–1.2) 0.8 (0.5–1.2) 1.0 (0.7–1.4)**
(Components of) the metabolic syndrome and insulin resistance
Metabolic syndrome 115 (26.9%) 77 (22.7%) 38 (43.3%)*
Glucometabolic disorders 101 (23.5%) 71 (20.7%) 30 (34.4%)**
High triglycerides 78 (17.6%) 51 (14.4%) 27 (30.0%)**
Low HDL-cholesterol 141 (31.8%) 102 (28.9%) 39 (43.3%)***
Hypertension 102 (23.3%) 77 (21.8%) 26 (28.9%)
Insulin resistance 209 (47.2%) 155 (43.9%) 54 (60.0%)**
Data are mean ± SD and n (%) or median (interquartile range) for variables with a skewed distribution
P values are given for comparisons between normal and high ALT groups tested with independent sample t tests, nonparametric tests, and χ2 tests
SD standard deviation, Z-BMI standard deviation score of BMI, Z-WC standard deviation score of waist circumference, ALT alanine
aminotransferase, HOMA-IR homeostasis model assessment for insulin resistance
*P<0.001; **P<0.01; ***P<0.05 for comparisons between the ALT ≤30 and ALT >30 IU/l groups
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Results
General characteristics of the study population
Table 2 shows the baseline characteristics of the study
population. The cohort comprised mainly four different
ethnic groups: Dutch native (19.0%), Turkish (27.5%),
Moroccan (25.5%), and Surinamese (9.7%). The remaining
children (18.3%) were of diverse origins, including Asian,
African, and South-American or had parents with different
ethnic backgrounds.
The median age of the participants was 11.2 years, with
ages ranging from 3.1 to 18.0 years. Boys had a higher
mean Z-BMI (2.9 vs. 2.7, P=0.002) as well as a higher Z-
WC compared to girls (4.3 vs. 3.5, P<0.001). Seventy
children (15.8%) were classified as overweight (12.9%
boys, 19.2% girls) and 373 (84.2%) as obese (87.1% boys,
80.8% girls).
The metabolic syndrome was detected in 26.9% of the
children, with a similar prevalence in boys and girls.
Glucometabolic disorders were present in 23.5%, high
triglycerides in 17.6%, low HDL-cholesterol in 31.8%, and
hypertension in 23.3% of the participants. Of the children
with glucometabolic disorders, 20.5% had IFG, 1.6% had
IGT, and 0.5% had type 2 diabetes. Insulin resistance was
present in 47.2% of the children. Elevated ALT levels
(>30 IU/l) were found in 20.3% of the study population,
with a higher prevalence found in boys than in girls
(25.8% vs. 13.8%, P<0.001). In addition, male subjects
had higher median ALT values in comparison with their
female peers (median 28, IQR 18–31 vs. median 23 IQR
15–26 IU/l, P<0.001). The difference in prevalence of
abnormal ALT values between the pubertal and prepubertal
group was not statistically significant (22.5% vs. 16.6%,
P=0.14).
There were no significant differences in prevalence of (the
components of) the metabolic syndrome or high ALT between
the overweight and obese group (data not shown). Therefore,
overweight and obese children were pooled for the univariate
and multivariate analyses. Among the ethnic groups, no
significant differences in prevalence of elevated ALT values
or meanALT values were found. In addition, no ethnic-related
differences were found in the prevalence of the various
cardiometabolic risk factors, except for the prevalence of
insulin resistance and the metabolic syndrome, both of which
were highest in Turkish children, as compared to their peers of
other origins (56.4% vs. 43.4%, P=0.019 and 35.2% vs.
23.7%, P=0.016, respectively).
Apart from obesity, 38.8% of the children had no
components of the metabolic syndrome, while 34.3% had
one component. The prevalence of the number of children
who had two components was 19.6%, and for more than
two the occurrence was 7.3%.
Prevalence and associations of cardiometabolic risk factors
and insulin resistance according to ALT
Table 2 shows the biochemical variables and prevalence of
the different cardiometabolic risk factors in the two ALT
groups (high ALT group [>30 IU/l] and normal ALT group
[≤30 IU/l]). The prevalence of the metabolic syndrome and
three of its components (high triglycerides, low HDL-
cholesterol, and glucometabolic disorders) were significant-
ly higher in the high ALT group, in comparison with the
normal ALT group (P<0.001 for the metabolic syndrome,
P=0.001 for high triglycerides, P=0.011 for low HDL-
cholesterol, and P=0.008 for glucometabolic disorders). In
addition, insulin resistance was more abundant in the high
ALT group (P=0.007). The mean number of components of
the metabolic syndrome was 0.9 in the low ALT group and
1.4 in the high ALT group (P<0.001).
Z-BMI was more strongly associated with ALT than the
Z-values of waist circumference (beta, 0.05; 95% confi-
dence interval (95% CI); 0.01–0.09 vs. beta, 0.02; 95% CI,
0.004–0.04, respectively). We found a strong association
between ALT and the metabolic syndrome (odds ratio (OR),
7.1; 95% CI, 2.3–21.5), adjusted for age, gender, and Z-
BMI, which remained significant after additional adjust-
ment for insulin resistance (OR, 3.6; 95% CI, 2.1–6.1).
With regard to the individual components of the metabolic
syndrome, ALT was associated with high triglycerides and
low HDL-cholesterol (OR, 10.3; 95% CI, 3.0–35.3 and OR,
3.9; 95% CI, 1.4–11.0, respectively), but not with gluco-
metabolic disorders and hypertension. Moreover, ALT was
Table 3 Associations of ALT with metabolic variables and blood
pressure
Variable Beta (95%CI) P value
Fasting glucose (mmol/l) −0.002 (−0.03 to 0.02) 0.865
2-hour glucose (mmol/l) 0.08 (0.01–0.14) 0.017
HOMA-IR
- Prepubertal 0.42 (0.18–0.65) 0.001
- Pubertal 0.48 (0.25–0.71) <0.001
Total cholesterol (mmol/l) 0.04 (−0.006 to 0.09) 0.088
HDL-cholesterol (mmol/l)
- Male −0.02 (−0.04 to 0.007) 0.163
- Female −0.04 (−0.07 to −0.008) 0.013
LDL-cholesterol (mmol/l) 0.04 (0.003–0.09) 0.036
Triglycerides (mmol/l)
- Prepubertal 0.04 (−0.01 to 0.10) 0.130
- Pubertal 0.06 (0.004–0.11) 0.037
Systolic blood pressure 0.30 (−0.38 to 0.98) 0.390
Diastolic blood pressure 0.26 (−0.23 to 0.76) 0.297
All variables are tested with regression analyses
Beta values are given for each ten unit increase in ALT after
adjustment for age, gender, and Z-BMI
Z-BMI standard deviation score of BMI, ALT alanine aminotransfer-
ase, HOMA-IR homeostasis model assessment for insulin resistance
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associated with insulin resistance (OR, 4.1; 95% CI, 1.3–
13.1).
Table 3 shows the beta values for the association of ALT
and different metabolic variables including glucose, lipids,
HOMA-IR, and blood pressure, per increase of ten units of
ALT, adjusted for age, gender, and BMI. These associations
were significant for all lipid levels (except for total
cholesterol), as well as for fasting insulin levels, 2h-glucose
levels, and HOMA-IR, after adjustment for age, gender, and
Z-BMI. Interestingly, no significant association was found
between ALT and fasting plasma glucose in obese children,
and a negative association was even seen in overweight
children.
It is of notice that the association between ALT and
several different variables (fasting insulin levels, HOMA-
IR, and triglycerides) were significantly influenced by
pubertal status (effect modifier), while the association
between ALT and low HDL-cholesterol was influenced by
gender. After stratification of these data, the association
between elevated ALT and triglycerides remained signifi-
cant only in the pubertal group, while fasting insulin levels
and HOMA-IR remained significant in both the prepubertal
and pubertal groups. HDL-cholesterol was only significant-
ly associated with ALT in females.
Discussion
The main findings of this observational study are the high
prevalence of cardiometabolic risk factors, including the
metabolic syndrome and elevated ALT, as a marker of
NAFLD in an obese multi-ethnic pediatric cohort.
There is no consensus regarding the definition of the
metabolic syndrome in children, due to a lack of uniformity
in the components and their cut-off values, taking into
account age, gender, pubertal status, and ethnicity. In a
previous report among 86 prepubertal and 105 pubertal
children, with comparable criteria for the metabolic
syndrome as in our study, the prevalence of the metabolic
syndrome varied from 12.0% (moderately obese) to 31.1%
(severely obese) [7]. It is of notice that, when the recently
proposed IDF-criteria are applied [2], the prevalence of the
metabolic syndrome in our population would equal 25.7%.
Still, the two definitions have no total overlap; only 72.0%
of the children would meet the criteria for both definitions
of the metabolic syndrome (data not shown). In addition to
the high prevalence of the lipid criteria of the metabolic
syndrome, which include low HDL-cholesterol and high
triglycerides, we found elevated total cholesterol in 12.0%
and high LDL-cholesterol levels in 16.3% of children, both
corrected for age and gender.
Our study is the first to report the prevalence of
cardiometabolic risk factors in a large number of children
of multiethnic origin in the Netherlands. In a recent Dutch
study in adults, the prevalence of the metabolic syndrome
(IDF-criteria) was highest in Hindustani Surinamese men
followed by African Surinamese and Dutch men, occurring
in 51.0%, 31.2%, and 19.4%, respectively, and for women,
both the Hindustani and African Surinamese participants
had a higher prevalence of the metabolic syndrome than
those of Dutch origin [5]. Among obese Turkish children
living in Turkey [1], hypertension was present in 15.7%
and the metabolic syndrome in 21.0%, whereas 29.2% had
either low HDL-cholesterol or high triglycerides (in our
study nearly 50%, with no significant differences among
ethnicities). These numbers indicate less dyslipidemia
among Turks living in Turkey, presumably due to different
dietary habits. According to our findings, Turkish children
are more insulin resistant (as determined by HOMA-IR)
and have higher prevalence of the metabolic syndrome than
their peers from other ethnic groups. In a previous study,
the metabolic syndrome, but not HOMA-IR, independently
predicted subclinical atherosclerosis and incident cardio-
vascular disease [4]. Thus, although insulin resistance is
correlated with the metabolic syndrome, it may not enclose
all the cardiometabolic risk factors associated with insulin
resistance. Still, given the high prevalence of the metabolic
syndrome in our Turkish children, they may be at greater
risk for developing cardiovascular disease later in life.
Hyperinsulinemia and insulin resistance, as confirmed by
hyperinsulinemic-euglycemic clamps, are generally more
abundant among pubertal children in comparison with
prepubertal populations. Decreased glucose oxidation and
increased free fatty acid (FFA) oxidation characterize pubertal
insulin resistance, partially mediated by the growth hormone/
insulin-like growth factor-I (GH/IGF-I) axis. We found a high
prevalence of IFG in our cohort (13.5% in prepubertal and
24.6% in pubertal children). This may be due to the cut-off
value of 5.6 mmol/l for fasting glucose which might be too
low (especially in prepubertal children) [30], but could also
indicate impaired basal insulin secretion and hepatic insulin
resistance in these children [19].
ALT is regarded as a marker of NAFLD [23]. Whereas
the sole determination of ALT does not prove the existence
of NAFLD, a strong correlation was found between ALT
and hepatic steatosis measured by proton magnetic reso-
nance spectroscopy (1H-MRS) even after adjustment for
BMI, ethnicity, gender, and age [6]. Conversely, in the
same study, only 48% of subjects with a fatty liver had
abnormal ALT levels, indicating that our data may
underestimate the prevalence of NAFLD in our population.
To note, the prevalence of NAFLD in obese children in
Western populations ranges from 9.5% (according to ALT
>30 IU/l) [26] to 38% (based on >5% hepatocytes
containing fat) [24] and 44% (based on liver ultrasound)
[21].
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We confirmed a higher prevalence of elevated ALT in
pubertal boys, as compared to girls [25]. This gender-
difference may be explained by the preferential intra-
abdominal location of fat in males which may predispose
for the development of NAFLD [25]. Also, the lower levels
of sex hormone binding globulin in men, which, together
with the ensuing higher levels of free, metabolically active
androgens, are associated with insulin resistance and a high
risk of NAFLD [13]. Finally, the difference in prevalence of
NAFLD between boys and girls may be due to a larger liver
mass in males. The role of pubertal stage in the develop-
ment of fatty liver remains controversial since contradictive
findings have been reported. Apparently, other factors
beside insulin resistance are involved in the pathogenesis
of NAFLD.
Previous studies have shown that ethnicity can influence
the risk for developing NAFLD; Hispanic populations were
shown to carry a high risk [25]. In our study, we found no
differences in ALT values or the presence of high ALT
among the ethnic groups.
As supported by previous published data [17, 21], ALT
was independently associated with insulin resistance.
Interestingly, we found no association between ALT and
fasting glucose, which is regarded as a result of the
contribution of hepatic insulin resistance, but most impor-
tantly, of beta-cell dysfunction. Overall, it may be conclud-
ed that, although previous reports have described beta cell
dysfunction in obese pediatric populations [14], beta-cell
dysfunction at a young age may be less explicit. The
significant association of ALT and fasting plasma trigly-
cerides in pubertal but not prepubertal children indicates a
sequence of the developmental stages of hepatic insulin
resistance over time.
In a longitudinal study in adults, elevated ALT was
associated with an increased incidence of the metabolic
syndrome [14], a finding which sheds light on the possible
causative role of NAFLD in the development of the clustered
cardiometabolic risk factors. In young adults, ALT predicted
cardiometabolic risk factors, even within the ALT reference
range [20], and ALT was shown to predict cardiovascular
disease in adults with and without type 2 diabetes [22]. The
‘portal hypothesis’, which implicates that abundant insulin-
resistant visceral fat increases lipolytic activity and, conse-
quently, the delivery of free fatty acids to the liver, as well as
an important role for dietary fat, as a major contributor to the
development of NAFLD, are among the explanations of the
pathophysiology of NAFLD [20, 22].
This study has several limitations, including the lack of a
normal-weight control group, which precluded generaliza-
tion of our results. Also, since the cut-off points for the
various components of the metabolic syndrome may not be
totally applicable to our population, some misclassification
cannot be ruled out. In addition, other forms of liver disease
that could result in elevated ALT levels besides hepatitis B
and C (such as alpha-1 antitrypsin deficiency) have not
been excluded in this study. Finally, the amount of dietary
fat intake, as a risk factor for NAFLD, was not assessed.
In conclusion, in an obese multiethnic pediatric population,
elevated ALT, suggestive of the presence of NAFLD, was
highly prevalent and associated with (components of) the
metabolic syndrome and insulin resistance. These associations
were independent of ethnicity, but in part depended on gender
and pubertal stage. Longitudinal large-scaled studies in
children and adolescents should establish the predictive value
of elevated ALT for the risk of developing type 2 diabetes and
cardiovascular disease in adulthood.
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